Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors

Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors

Introduction: To evaluate the impact of Sars-Cov-2 infection on mortality and immune checkpoint inhibitor (ICI) toxicity in patients with cancer receiving ICIs compared to those not receiving ICIs. Methods: We conducted a retrospective matched cohort study of 25 patients receiving ICIs within 1 year...

Full description

Bibliographic Details
Main Authors: Ai-Tram N. Bui, Kevin Tyan, Anita Giobbie-Hurder, Isaac A. Klein, Michael P. Manos, Leyre Zubiri, Kerry Reynolds, Shilpa Grover, Gerald L. Weinhouse, Patrick A. Ott, Nicole R. LeBoeuf, Osama Rahma
Format: Article
Language:English
Published: Innovative Healthcare Institute 2021-05-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
covid-19
immune checkpoint inhibitors
programmed death 1
programmed death ligand 1
cytotoxic t-lymphocyte–associated protein 4
immune-related adverse events
cancer
Online Access:https://jipo.org/doi/pdf/10.36401/JIPO-20-34

Internet

https://jipo.org/doi/pdf/10.36401/JIPO-20-34

Similar Items